SFB1399: Univ. Prof. Dr. rer. nat. Hans-Georg Rammensee

Academic education

1974 - 1980: Biology studies at the University of Tübingen
1980: Diploma thesis in the laboratory of Professor Dr. Jan Klein at the Max Planck Institute for Biology, Tübingen

Scientific degrees

1991: Habilitation (postdoctoral teaching qualification) in immunology, University of Tübingen
1980 - 1982: PhD Thesis ("Dr. rer. nat.") at the Max Planck Institute for Biology on minor histocompatibility antigens (Supervisor: Professor Dr. Jan Klein)

Scientific career

2019 - 2024: Co-chair of the Excellenzcluster 2180 "Image-guided and Functionally Instrcuted Tumor Therapies (iFIT)
2012 - 2021: Deputy site coordinator of the German Consortium for Translational Cancer Research (DKTK) and overall coordinator of the DKTK research program Cancer Immunotherapy
2005 - 2017: Chairman of the SFB 685: Immunotherapy: Molecular basis and clinical application
2002 - 2012: Chairman of the Graduiertenkolleg 794: Graduate School for Cellular Mechanisms of Immune-associated Processes
2000: Co-founder of the biotechnology enterprises immatics GmbH and Curevac GmbH
1996 - 2023: Chair, Department of Immunology (Full Professor, C4), Institute for Cell Biology, University of Tübingen, Germany
1993 - 1996: Head of Department, Tumor-Virus-Immunology Section, German Cancer Research Center (DKFZ), Heidelberg; appointment as Professor, University of Heidelberg
1987 - 1993: Group leader at the Department of Immunogenetics, Max Planck Institute for Biology, Tübingen, Germany
1985 - 1987: Scientific Member of the Basel Institute for Immunology
1982 - 1985: Postdoctoral research fellow in the laboratory of Michael J. Bevan, PhD, at Scripps Clinic, La Jolla, CA, USA

Honors/ Awards/ Memberships

2023: CIMT Lifetime Achievement Award
2022: Member of the Leopoldina, Halle
2020: Landeforschungspreis Baden-Württemberg
2016: Ernst Jung Prize for Medicine
2016: Wilhelm Warner Foundation
2014: German Cancer Aid Award
2014: Advanced Grant, European Research Council (ERC)
2013: The Hansen Family Award, Bayer Science and Education Foundation
1997: Rose Payne Distinguished Scientist Award
1996: Paul Ehrlich und Ludwig Darmstaedter Prize
1993: Robert Koch Prize
1992: Avery Landsteiner Prize
1992: Gottfried Wilhelm Leibniz Prize
1991: Wilhelm und Maria Meyenburg Prize
1988: Heinz-Maier-Leibnitz Prize Krebsforschungszentrum

Membership in advisory boards (selection)

2011 - 2022: Member of the Scientific Advisory Board, RCI Regensburg Center for Interventional Immunology
2006 - 2021: Co-opted member of the Scientific Council of the Paul Ehrlich Foundation
2002 - present: Co-founder and board member of the Association for Cancer Immunotherapy (CIMT)
1998 - 2018: Board member of the Cooperation Program in Cancer Research (German Cancer Research Center Heidelberg and the Ministry of Science, Israel)

10 most relevant publications

Rammensee HG, Gouttefangeas C, Heidu S, Klein R, Preuss B, Walz JS, Nelde A, Haen SP, Reth M, Yang J, Tabatabai G, Bosmuller H, Hoffmann H, Schindler M, Planz O, Wiesmuller KH, and Loffler MW. Designing a sars-cov-2 t-cell-inducing vaccine for high-risk patient groups. Vaccines (Basel) 2021; 9.
Schollhorn A, Schuhmacher J, Besedovsky L, Fendel R, Jensen ATR, Stevanovic S, Lange T, Rammensee HG, Born J, Gouttefangeas C, and Dimitrov S. Integrin activation enables sensitive detection of functional cd4(+) and cd8(+) t cells: Application to characterize sars-cov-2 immunity. Front Immunol 2021; 12: 626308.
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lubke M, Bauer J, Rieth J, Wacker M, Peter A, Horber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jager E, Graf M, Gruber LC, Rachfalski D, Preuss B, Hagelstein I, Marklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanovic S, Rammensee HG, and Walz JS. Sars-cov-2-derived peptides define heterologous and covid-19-induced t cell recognition. Nat Immunol 2021; 22: 74-85.
Rammensee HG, Wiesmuller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bodder J, Schertel JM, Tunger A, Muller L, Kiessler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougere C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanovic S, and Loffler MW. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J Immunother Cancer 2019; 7: 307.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, and Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019; 565: 240-245.
Falk K, Rotzschke O, Stevanovic S, Jung G, and Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from mhc molecules. Nature 1991; 351: 290-6.
Schuster H, Peper JK, Bosmuller HC, Rohle K, Backert L, Bilich T, Ney B, Loffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanovic S, Staebler A, and Wagner P. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 2017; 114: E9942-E9951.
Nelde A, Flototto L, Jurgens L, Szymik L, Hubert E, Bauer J, Schliemann C, Kessler T, Lenz G, Rammensee HG, Walz JS, and Wethmar K. Upstream open reading frames regulate translation of cancer-associated transcripts and encode hla-presented immunogenic tumor antigens. Cell Mol Life Sci 2022; 79: 171.
Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, Reusch J, Jager S, Denk M, Richter M, Anton L, Weber LM, Roerden M, Bauer J, Rieth J, Wacker M, Horber S, Peter A, Meisner C, Fischer I, Loffler MW, Karbach J, Jager E, Klein R, Rammensee HG, Salih HR, and Walz JS. A covid-19 peptide vaccine for the induction of sars-cov-2 t cell immunity. Nature 2022; 601: 617-622.
Nelde A, Maringer Y, Bilich T, Salih HR, Roerden M, Heitmann JS, Marcu A, Bauer J, Neidert MC, Denzlinger C, Illerhaus G, Aulitzky WE, Rammensee HG, and Walz JS. Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia. Front Immunol 2021; 12: 705974.

Patents

More than 140 registered or pending patents

Companies

Co-founder of the biotechnology enterprises immatics GmbH, Curevac GmbH, Synimmune GbH, Bamomab GmbH, Viferaxy GmbH.

CV

Univ. Prof. Dr. rer. nat. Hans-Georg Rammensee